A new analysis in Cell Death Discovery argues that cell therapy programs are repeatedly failing at IND and BLA/NDA gates due to technical and documentation mismatches rather than purely clinical shortcomings. The report highlights a recurring problem: even when the biological rationale looks compelling, regulators can view product characterization, release documentation, and technical evidence as incomplete or inconsistent. The findings focus on why regulatory submissions stall or fail—emphasizing the need for better alignment between biological claims and the data packages used to support safety and quality. It also underscores that manufacturing complexity and variability can become regulatory vulnerabilities if not addressed with stronger process-control evidence. For developers, the message is clear: submission readiness must be engineered into the product development lifecycle, not treated as an afterthought once trials finish.